Alison D Gernand1, Hyagriv N Simhan, Steve Caritis, Lisa M Bodnar. 1. Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, the Division of Maternal-Fetal Medicine, Magee-Women's Hospital, and the Departments of Obstetrics, Gynecology and Reproductive Sciences and Pediatrics, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.
Abstract
OBJECTIVE: To examine the association between second-trimester maternal serum 25-hydroxyvitamin D concentrations and risk of small for gestational age (SGA) in singleton live births. METHODS: We assayed serum samples at 12-26 weeks of gestation for 25-hydroxyvitamin D in a sample of participants in a multicenter clinical trial of low-dose aspirin for the prevention of preeclampsia in high-risk women (n=792). Multivariable log-binomial regression models were used to assess the association between 25-hydroxyvitamin D and risk of SGA (birth weight less than the 10 percentile for gestational age) after adjustment for confounders including maternal prepregnancy obesity, race, treatment allocation, and risk group. RESULTS: Thirteen percent of neonates were SGA at birth. Mean (standard deviation) 25-hydroxyvitamin D concentrations were lower in women who delivered SGA (57.9 [29.9] nmol/L) compared with non-SGA neonates (64.8 [29.3] nmol/L, P=.028). In adjusted models, 25-hydroxyvitamin D concentrations of 50-74 nmol/L and 75 nmol/L or greater compared with less than 30 nmol/L were associated with 43% (95% confidence interval [CI] 0.33-0.99) and 54% (95% CI 0.24-0.87) reductions in risk of SGA, respectively. Race and maternal obesity each modified this association. White women with25-hydroxyvitamin D 50 nmol/L or greater compared with less than 50 nmol/L had a 68% reduction in SGA risk (adjusted risk ratio 0.32, 95% CI 0.17-0.63) and nonobese women with 25-hydroxyvitamin D 50 nmol/L or greater compared with less than 50 nmol/L had a 50% reduction in SGA risk (adjusted risk ratio 0.50, 95% CI 0.31-0.82). There was no association between 25-hydroxyvitamin D and risk of SGA in black or obese mothers. CONCLUSION:Maternal vitamin D status in the second trimester is associated with risk of SGA among all women and in the subgroups of white and nonobese women. LEVEL OF EVIDENCE: II.
RCT Entities:
OBJECTIVE: To examine the association between second-trimester maternal serum 25-hydroxyvitamin D concentrations and risk of small for gestational age (SGA) in singleton live births. METHODS: We assayed serum samples at 12-26 weeks of gestation for 25-hydroxyvitamin D in a sample of participants in a multicenter clinical trial of low-dose aspirin for the prevention of preeclampsia in high-risk women (n=792). Multivariable log-binomial regression models were used to assess the association between 25-hydroxyvitamin D and risk of SGA (birth weight less than the 10 percentile for gestational age) after adjustment for confounders including maternal prepregnancy obesity, race, treatment allocation, and risk group. RESULTS: Thirteen percent of neonates were SGA at birth. Mean (standard deviation) 25-hydroxyvitamin D concentrations were lower in women who delivered SGA (57.9 [29.9] nmol/L) compared with non-SGA neonates (64.8 [29.3] nmol/L, P=.028). In adjusted models, 25-hydroxyvitamin D concentrations of 50-74 nmol/L and 75 nmol/L or greater compared with less than 30 nmol/L were associated with 43% (95% confidence interval [CI] 0.33-0.99) and 54% (95% CI 0.24-0.87) reductions in risk of SGA, respectively. Race and maternal obesity each modified this association. White women with 25-hydroxyvitamin D 50 nmol/L or greater compared with less than 50 nmol/L had a 68% reduction in SGA risk (adjusted risk ratio 0.32, 95% CI 0.17-0.63) and nonobese women with 25-hydroxyvitamin D 50 nmol/L or greater compared with less than 50 nmol/L had a 50% reduction in SGA risk (adjusted risk ratio 0.50, 95% CI 0.31-0.82). There was no association between 25-hydroxyvitamin D and risk of SGA in black or obese mothers. CONCLUSION: Maternal vitamin D status in the second trimester is associated with risk of SGA among all women and in the subgroups of white and nonobese women. LEVEL OF EVIDENCE: II.
Authors: J M Franasiak; X Wang; T A Molinaro; K Green; W Sun; M D Werner; C R Juneau; R T Scott Journal: Endocrine Date: 2016-04-06 Impact factor: 3.633
Authors: Christopher R Sudfeld; Denise L Jacobson; Noé M Rueda; Daniela Neri; Armando J Mendez; Laurie Butler; Suzanne Siminski; Kristy M Hendricks; Claude A Mellins; Christopher P Duggan; Tracie L Miller Journal: J Acquir Immune Defic Syndr Date: 2019-07-01 Impact factor: 3.731
Authors: Claire Casey; Ann McGinty; Valerie A Holmes; Chris C Patterson; Ian S Young; David R McCance Journal: Br J Nutr Date: 2018-07 Impact factor: 3.718